Cinaxadamtase alfa is a Recombinant Enzyme owned by KM Biologics, and is involved in 8 clinical trials, of which 5 were completed, 2 are ongoing, and 1 is planned.

Cinaxadamtase alfa (TAK-755, SHP-655, recombinant ADAMTS13 replenishes the function of patients’ inactivated ADAMTS13. ADAMTS13 normally breaks down large aggregations of a substance in the body called von Willebrand factor, which is involved in the blood clotting process by linking to platelets. When ADAMTS13 is inactivated, the aggregations of von Willebrand factor are not broken down and more blood clots are formed in the blood vessels. It reconstitutes ADAMTS13 and prevents clotting of blood.

The revenue for Cinaxadamtase alfa is expected to reach a total of $4.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cinaxadamtase alfa NPV Report.

Cinaxadamtase alfa was originated by Kaketsuken and is currently owned by KM Biologics. Takeda Pharmaceutical is the other company associated in development or marketing of Cinaxadamtase alfa.

Cinaxadamtase alfa Overview

Cinaxadamtase alfa is under development for the treatment and prophylaxis of congenital thrombotic thrombocytopenic purpura (hTTP), immune thrombotic thrombocytopenic purpura (ITTP), sickle cell disease. It is administered intravenously. The drug candidate is a bio-engineered version of a naturally occurring Von Willebrand factor cleaving protease enzyme (ADAMTS13).

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Cinaxadamtase alfa

Report Segments
  • Innovator
Drug Name
  • Cinaxadamtase alfa
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.